



- (51) **International Patent Classification:**
A61K 9/48 (2006.01) *A61K 31/506* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/056935
- (22) **International Filing Date:**
17 July 2024 (17.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/514,039 17 July 2023 (17.07.2023) US
- (71) **Applicant:** **GRAVITON BIOSCIENCE BV** [NL/NL];
Herengracht 540, 1017 CG Amsterdam (NL).
- (72) **Inventors:** **WAKSAL, Samuel D.**; c/o Graviton Bioscience, 125 West End Ave, Suite 301, New York, New York 10023 (US). **WU, Rui**; c/o Graviton Bioscience, 125 West End Ave, Suite 301, New York, New York 10023 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

- (54) **Title:** FORMULATIONS AND USES OF ROCK2 INHIBITORS FOR ALS

FIG. 1



- (57) **Abstract:** Provided herein, inter alia, pharmaceutical formulations for oral administration of ROCK2 inhibitors (e.g., compound A). Also provided are methods for treating a neurodegenerative disease characterized by the degeneration of motor neurons, and particularly amyotrophic lateral sclerosis (ALS), the method comprising administering to the subject in need thereof a therapeutically effective amount of a ROCK2 inhibitor.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*